Mazdutide
About
About Mazdutide
Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist in late-stage clinical development showing compelling weight loss data in trials conducted primarily in Asia. It targets both energy intake (via GLP-1) and energy expenditure (via glucagon), a mechanistically differentiated approach from semaglutide. Phase III trials report 15–18% body weight reduction. It is not yet FDA-approved but may reach Western markets by 2026–2027.
Science
Mechanism of Action
Simultaneous activation of GLP-1 and glucagon receptors produces appetite suppression via the hypothalamus while glucagon signaling increases hepatic glucose output and thermogenic energy expenditure.
Dosing
Typical Protocol
3–9 mg subcutaneous injection once weekly; currently available through research access outside the US.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Mazdutide — with trust scores, legal credentials, and pricing transparency.